M. Lau
GlaxoSmithKline
24 Papers
66 Citations
M. Lau is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 13 publications.
Chat about Author
Papers
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P. Vellano,Michael G. White,Miles C. Andrews,Manoj Chelvanambi,Russell Witt,Joseph R. Daniele,Mark Titus,Jennifer L. McQuade,Fabio Conforti,Elizabeth M. Burton,Matthew J. Lastrapes,Gabriel Ologun,Alexandria P. Cogdill,Golnaz Morad,Peter A. Prieto,Alexander J. Lazar,Yan-Jun Chu,Guangchun Han,M.A. Wadud Khan,Beth A. Helmink,Michael Davies,Rodabe N. Amaria,Jeffrey J. Kovacs,Scott E. Woodman,Sapna Pradyuman Patel,Patrick Hwu,Michael Peoples,Jeffrey E. Lee,Zachary A. Cooper,Haifeng Zhu,Guang Gao,Hiya Banerjee,M. Lau,Jeffrey E. Gershenwald,Anthony Lucci,Emily Z. Keung,Merrick I. Ross,Laura Pala,Eleonora Pagan,Rossana Lazcano Segura,Qian Liu,Mikayla S. Borthwick,Eric Lau,Melinda S. Yates,Shannon N. Westin,Khalida Wani,Michael T. Tetzlaff,Lauren E. Haydu,Mikhila Mahendra,Xiaoyan Ma,Christopher J. Logothetis,Zachary Kulstad,Sarah B. Johnson,Courtney W. Hudgens,Ningping Feng,Lorenzo Federico,Georgina V. Long,P. Andrew Futreal,Swathi Arur,Hussein Abdul-Hassan Tawbi,Amy E. Moran,Linghua Wang,Timothy P. Heffernan,Joseph R. Marszalek,Jennifer A. Wargo +64 more
TL;DR: In this article , a group of patients with melanoma who were treated with neoadjuvant BRAF/MEK-targeted therapy (NCT02231775 , n = 51) and observed significantly higher rates of major pathological response (MPR; ≤ 10% viable tumour at resection) and improved recurrence-free survival (RFS) in female versus male patients.
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
Azeem Saleem,Graham E. Searle,Laura M. Kenny,Mickael Huiban,Kasia Kozlowski,Adam D. Waldman,Laura Woodley,Carlo Palmieri,Charles Lowdell,Tomomi Kaneko,Philip S. Murphy,M. Lau,Eric O. Aboagye,Raoul Charles Coombes +13 more
TL;DR: Increased Lapatinib uptake was observed in brain metastases but not in normal brain, suggesting no effect of increased drug access by inhibition of the drug efflux proteins by therapeutic doses of lapatinib.
69
Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).
Kevin J. Harrington,A. Berrier,Martin Robinson,Éva Remenár,M. Housset,F. Hurtado de Mendoza,Natalie Compton,M. Lau,Philippe Legenne,Ritesh Kumar +9 more
TL;DR: Lapatinib is an oral, reversible small-molecule inhibitor of epidermal growth factor receptor (EGFR) and human Epidermal Growth Factor receptor-2 (HER2) and EGFR overexpression is reported to be a novel mechanism of action for EGFR inhibition.
27
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Rodryg Ramlau,Michael Thomas,Silvia Novello,Ruth Plummer,Martin Reck,Tomomi Kaneko,M. Lau,Jane Margetts,John Lunec,J E Nutt,Giorgio V. Scagliotti +10 more
TL;DR: A dose-escalation study of lapatinib combined with pemetrexed in second-line treatment to evaluate the safety and efficacy in advanced or metastatic non-small-cell lung cancer (NSCLC) and an exploratory study in which circulating cell-free thymidylate synthase ribonucleic acid (cfTSmRNA) was measured in all patients and compared with clinical benefit are reported.
17
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
John Crown,M.J. Kennedy,P. Tresca,Michel Marty,M. Espie,Howard A. Burris,M. DeSilvio,M. Lau,D. Kothari,Kevin M. Koch,Véronique Diéras +10 more
TL;DR: Lapatinib/docetaxel/trastuzumab is a feasible and well-tolerated treatment of untreated HER2-positive stage IV MBC.
16